期刊
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
卷 130, 期 3, 页码 394-414出版社
WILEY
DOI: 10.1111/bcpt.13695
关键词
congenital malformation; polymorbidity; polypharmacy; pregnancy; systematic review
资金
- Aarhus Universitet
The study evaluated the risk of congenital malformations in polymorbid pregnancies exposed to first-trimester polypharmacy, and found that there is an increased risk of malformations in such cases. It is recommended to enhance pharmacovigilance to ensure safe drug use in early pregnancy.
With an increased prevalence of concurrent morbidities during pregnancy, polypharmacy has become increasingly common in pregnant women. The risks associated with polypharmacy may exceed those of individual medication because of drug-drug interactions. This systematic review aims to evaluate the risk of congenital malformations in polymorbid pregnancies exposed to first-trimester polypharmacy. PubMed, Embase and Scopus were searched to identify original human studies with first- trimester polypharmacy due to polymorbidity as the exposure and congenital malformations as the outcome. After screening of 4034 identified records, seven studies fulfilled the inclusion criteria. Four of the seven studies reported an increased risk of congenital malformations compared with unexposed or monotherapy, odds ratios ranging from 1.1 to >10.0. Particularly, short-term anti-infective treatment combined with other drugs and P-glycoprotein substrates were associated with increased malformation risks. In conclusion, knowledge is limited on risks associated with first-trimester polypharmacy due to polymorbidity with the underlying evidence of low quantity and quality. Therefore, an increased focus on pharmacovigilance to enable safe drug use in early pregnancy is needed. Large-scale register-based studies and better knowledge of placental biology are needed to support the clinical management of polymorbid pregnancies that require polypharmacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据